We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
Ikena Oncology Inc is a targeted oncology company developing precision medicines tailored to biomarker-defined patient groups with specific unmet needs. Its lead targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD... Ikena Oncology Inc is a targeted oncology company developing precision medicines tailored to biomarker-defined patient groups with specific unmet needs. Its lead targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, transcription factor in the Hippo signaling pathway. The Hippo pathway is genetically altered in approximately 10% of human cancers and is widely accepted as a prevalent driver of cancer pathogenesis and a mediator of poor outcomes for patients. Show more
Ikena to discontinue development of IK-930 IK-595 dose escalation continues in RAS and RAF mutant cancers; Encouraging PK and PD profile shown to date Ended first quarter with $157.3 million;...
Ikena to discontinue development of IK-930 IK-595 dose escalation continues in RAS and RAF mutant cancers; Encouraging PK and PD profile shown to date Ended first quarter with $157.3 million;...
Strong financial position with $157.3 million; runway into 2H 2026 IK-930 program on track to deliver clinical update in 2H 2024 IK-595 program continues dose escalation in patients with RAS and...
BOSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today...
IK-930 continues to advance in the clinic now with an optimized formulation with improved pharmacokinetics IK-930 clinical update planned for 2H 2024 including additional data from EHE patients...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.065 | -3.73563218391 | 1.74 | 1.7794 | 1.63 | 97215 | 1.6877671 | CS |
| 4 | -0.015 | -0.887573964497 | 1.69 | 1.78 | 1.6 | 160011 | 1.66812801 | CS |
| 12 | 0.375 | 28.8461538462 | 1.3 | 1.89 | 1.28 | 285121 | 1.59570896 | CS |
| 26 | 0.135 | 8.76623376623 | 1.54 | 1.89 | 1.22 | 354096 | 1.48297939 | CS |
| 52 | -4.595 | -73.2854864434 | 6.27 | 6.44 | 1.02 | 252916 | 1.82685407 | CS |
| 156 | -9.965 | -85.6099656357 | 11.64 | 17.5 | 1.02 | 168692 | 4.41785155 | CS |
| 260 | -20.725 | -92.5223214286 | 22.4 | 37.61 | 1.02 | 173907 | 6.16787165 | CS |
Monksdream
2 days ago
Monksdream
2 weeks ago
glenn1919
2 months ago
Monksdream
4 months ago
Monksdream
5 months ago
herbied47
8 months ago
herbied47
8 months ago
Tacostocks
8 months ago
Money hunt
8 months ago
Tacostocks
8 months ago
AJ Freely
11 months ago
Tartiaboy
1 year ago
TrendTrade2016
2 years ago
TrendTrade2016
2 years ago
crudeoil24
3 years ago
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
